HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)

被引：0

作者：

Schernthaner, Guntram

Tinahones, Francisco J.

Goetz, Sophia

Lee, Christopher

机构：

来源：

DIABETES | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1288-P

引用

页码：A345 / A346

页数：2

共 50 条

[21] Individualized HbA1c targets in elderly patients with T2DM
Linda Koch
Nature Reviews Endocrinology, 2013, 9 (8) : 440 - 440
[22] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
Kohler, Sven
Salsali, Afshin
Hantel, Stefan
Kim, Gabriel
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2015, 64 : A302 - A303
[23] Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM)
Willis, Michael
Neslusan, Cheryl
Asseburg, Christian
He, Jianming
DIABETES, 2011, 60 : A68 - A68
[24] Empaglifl ozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 4 Years in Patients with Type 2 Diabetes (T2DM)
Ridderstrale, Martin
Robert, Knut
Toorawa, Andersen
Woerle, Hans J.
Salsali, Afshin
DIABETES, 2016, 65 : A47 - A48
[25] COORDINATION OF HBA1C AND LVDD IN T2DM WITH IHD
Mukhtarova, Shahnoza
Trigulova, Raisa
Akhmedova, Dilafruz
Alimova, Dilnoza
Akhmedova, Shokhistakhon
ATHEROSCLEROSIS, 2024, 399
[26] An average HbA1C of <7.0 is achievable in patients with T2DM
Hood, RC
DIABETES, 2002, 51 : A485 - A485
[27] Progression of microalbuminuria during a long-term open-label (OL) trial of pioglitazone (PIO) in patients with type 2 diabetes mellitus (T2DM)
Perez, A
Cichy, S
Glazer, B
DIABETES, 2002, 51 : A111 - A111
[28] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
Willis, M.
He, J.
Neslusan, C.
Johansen, P.
Worbes-cerezo, M.
VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
[29] Implications of Using the UKPDS HbA1c Equation in Economic Modeling of Type 2 Diabetes Mellitus (T2DM)
Willis, Michael
Asseburg, Christian
Johansen, Pierre
Schroeder, Melanie
Neslusan, Cheryl
DIABETES, 2016, 65 : A581 - A581
[30] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
Dejager, Sylvie
Lebeaut, Alexandre
Couturier, Andre
Schweizer, Anja
DIABETES, 2006, 55 : A29 - A29

← 1 2 3 4 5 →